Regulation Of Cyclic Nucleotide Phosphodiesterases Research Articles

Regulation of Cyclic Nucleotide Phosphodiesterase 1 by Endoplasmic Reticulum Stress Contributes to Homocysteine‐induced Cardiac Hypertrophy

Objectives Mechanistic understanding of the role of homocysteine in the development of cardiac hypertrophy is inadequate at present. This study aimed to elucidate the association of cyclic nucleotide phosphodiesterase 1 (PDE1) and endoplasmic reticulum (ER) stress with cardiomyocyte hypertrophy induced by homocysteine. Methods H9c2 cardiomyocytes were allocated to control group and homocysteine-treated group in the presence or absence of ER stress inhibitor tauroursodeoxycholic acid (TUDCA) or PDE1 inhibitor Lu AF58027 for 72h. In another set of experiment, H9c2 cells were transfected with specific siRNA targeting PDE1 subtypes prior to homocysteine exposure. The cell surface area was measured by phase contrast microscope and image analysis software and ultrastructural changes of the cells were observed under transmission electron microscopy. Quantitative polymerase chain reaction and western blot were employed to detect the mRNA and protein expression of the hypertrophic markers beta-smooth muscle myosin heavy chain (β-MHC) and atrial natriuretic peptide (ANP), PDE1 subtypes (PDE1A, 1B, and 1C), and ER stress molecules (GRP78, phosphor-PERK, PERK, phosphor-IRE1, IRE1, and ATF6). The intracellular levels of cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP) were measured by enzyme linked immunosorbent assay. Results Homocysteine exposure resulted in an enlargement in cell size and an increase in β-MHC and ANP expression. Homocysteine induced ER stress in H9c2 cells, shown by increased expression of GRP78 and enhanced phosphorylation of PERK and IRE1, as well as dilatation and degranulation of rough ER. The expression of PDE1A and PDE1C was significantly upregulated by homocysteine. Inhibition of ER stress or PDE1 suppressed homocysteine-induced upregulation of β-MHC and ANP and alleviated cell enlargement. In addition, the protein expression of PDE1A and PDE1C in homocysteine-exposed H9c2 cells was downregulated by the ER stress inhibitor TUDCA. Silencing of PDE1C significantly inhibited homocysteine-induced cell hypertrophy whereas knockdown of PDE1A showed minor effect. Both cAMP and cGMP levels were lowered in H9c2 cells subjected to homocysteine exposure, while only cAMP content could be restored by Lu AF58027 and TUDCA. Conclusions ER stress mediates homocysteine-induced cardiomyocyte hypertrophy via upregulating PDE1 expression. Cyclic nucleotide, in particular cAMP, is the downstream mediator of the ER stress-PDE1 signaling axis in homocysteine-induced hypertrophy.

Calcium/Calpain mediated regulation of cyclic nucleotide phosphodiesterases, PDE3A and PDE5, in human platelets

Background Calpain, intracellular non-lysosomal calcium-dependent proteinase, is activated by a number of signaling pathways that lead to the elevation of intraplatelet calcium concentrations. Physiological roles of calpain, highly expressed in platelets, include regulation of platelet aggregation and adhesion, while excessive activation of calpain in such pathological disorders as diabetes could cause changes in platelet functions, resulting in platelet hyperactivation. Platelets from diabetic patients are also characterized by resistance to nitric oxide inhibition. Here we examined if calpain could regulate major cAMP and cGMP hydrolyzing phosphodiesterases (PDEs), PDE3A and PDE5, in human platelets.

Expression and Regulation of Cyclic Nucleotide Phosphodiesterases in Human and Rat Pancreatic Islets

As shown by transgenic mouse models and by using phosphodiesterase 3 (PDE3) inhibitors, PDE3B has an important role in the regulation of insulin secretion in pancreatic β-cells. However, very little is known about the regulation of the enzyme. Here, we show that PDE3B is activated in response to high glucose, insulin and cAMP elevation in rat pancreatic islets and INS-1 (832/13) cells. Activation by glucose was not affected by the presence of diazoxide. PDE3B activation was coupled to an increase as well as a decrease in total phosphorylation of the enzyme. In addition to PDE3B, several other PDEs were detected in human pancreatic islets: PDE1, PDE3, PDE4C, PDE7A, PDE8A and PDE10A. We conclude that PDE3B is activated in response to agents relevant for β-cell function and that activation is linked to increased as well as decreased phosphorylation of the enzyme. Moreover, we conclude that several PDEs are present in human pancreatic islets.

The role of protein phosphorylation in the regulation of cyclic nucleotide phosphodiesterases.

The cyclic nucleotide phosphodiesterases constitute a complex superfamily of enzymes responsible for catalyzing the hydrolysis of cyclic nucleotides. Regulation of cyclic nucleotide phosphodiesterases is one of the two major mechanisms by which intracellular cyclic nucleotide levels are controlled. In many cases the fluctuations in cyclic nucleotide levels in response to hormones is due to the hormone responsiveness of the phosphodiesterase. Isozymes of the cGMP-inhibited, cAMP-specific, calmodulin-stimulated and cGMP-binding phosphodiesterases have been demonstrated to be substrates for protein kinases. Here we review the evidence that hormonally responsive phosphorylation acts to regulate cyclic nucleotide phosphodiesterases. In particular, the cGMP-inhibited phosphodiesterases, which can be phosphorylated by at least two different protein kinases, are activated as a result of phosphorylation. In contrast, phosphorylation of the calmodulin-stimulated phosphodiesterases, which coincides with a decreased sensitivity to activation by calmodulin, results in decreased phosphodiesterase activity.

Hormonal regulation of cyclic nucleotide phosphodiesterases.

I. Introduction ACOMPLEX array of signals from the extracellular environment regulate many cell processes, including the entry and exit from the mitotic cycle and the induction and maintenance of differentiation (1–3). Cells elaborate these external stimuli via receptors, transducers, and second messengers (4, 5) which control intricate circuits that lead to protein phosphorylation by protein kinases (6, 7). Although novel second messenger pathways have been discovered and dissected in some detail in the past 10 years (8, 9), cyclic nucleotides (cAMP and cGMP) remain the best characterized second messengers, and their role in the differentiation and control of metabolic processes of the endocrine cell is widely recognized. The components of the membrane-associated machinery that transduces external signals into changes in cyclic nucleotide levels have been isolated and characterized. These include many members of the family of membrane receptors (10–14), G proteins acting as transducers (15, 16), and aden...

Regulation of cyclic nucleotide phosphodiesterase forms by serum and insulin in cultured fibroblasts

A rapid reduction of cyclic nucleotide phosphodiesterase activity occurs after the replating of confluent cultures of BHK 21 c/13 fibroblasts into fresh medium. This reduction in activity depends on the density to which the cultures are reseeded and the concentration of serum in the medium. Enzyme activity in BHK cells is restored after 24 to 48 hours if cells are diluted into medium containing 10% fetal calf serum or 0.5% fetal calf serum supplemented with insulin (10(-6)M), but not into 0.5% serum alone. The restoration in enzyme activity is blocked by cycloheximide or Actinomycin D. When BHK cells become quiescent by maintanance in 0.5% serum conditions for 48 hours, a rapid (15--60 minutes) increase in cyclic AMP phosphodiesterase activity occurs when 10% serum is added to the cultures. Enzyme activity is increased even further after 24 to 48 hours in the 10% serum. Cycloheximide or Actinomycin D do not affect the rapid increase in enzyme activity in response to serum, but completely inhibit the long term increase. In contrast to serum, insulin (10(-8) to 10(-6)M) has no short term effect, but does increase enzyme activity after 24 to 48 hours to levels comparable to those seen with addition of 10% serum. As is the case with serum, this long term effect of insulin on enzyme activity is prevented by inhibitors of protein and RNA synthesis. Kinetic analyses of cyclic AMP phosphodiesterase activity in homogenates of quiescent BHK cells indicate the presence of only high Km (congruent to 20 muM) enzyme activity. Addition of serum or insulin to quiescent cells results in the appearance of apparent low Km enzyme activity in homogenates. Sucrose gradient analysis of BHK cells displays two forms of cyclic AMP phosphodiesterase enzyme activity: a 3--4 S form and 5--6 S form. In quiescent cells, the 5--6 S form greatly predominates relative to the 3--4 S form. Addition of serum to quiescent cells results in a rapid appearance of increased 3--4 S form enzyme activity. Insulin also increases the activity of this higher affinity 3--4 S enzyme form after 24 to 48 hours in culture. The functional significance of short and long term regulation of cyclic nucleotide phosphodiesterase(s) in cells is discussed.

Regulation of cyclic nucleotide phosphodiesterases in cultured hepatoma cells by dexamethasone and N6,O2'-dibutyryl adenosine 3':k'-monophosphate.

DEAE-Bio-Gel chromatography of 100,000 X g supernatant from cultured HTC hepatoma cells separated cyclic nucleotide phosphodiesterase into three forms, numbered E I, E II, and E III in order of elution from the column, E I had a low Km for cyclic guanosine 3':5'-monophosphate (cGMP) and a high Km for cyclic adenosine 3':5'-monophosphate (cAMP), E II exhibited anomalous kinetics. At low substrate concentrations (0.5 muM) cGMP was hydrolyzed more rapidly than cAMP and hydrolysis of 0.5 muM cAMP was stimulated by 1 muM cGMP. E III had a low Km for cAMP. Incubation of cells with 1 muM dexamethasone for 72 h decreased the activity of E I and E II. In cells incubated with N6,O2'-dibutyryl cAMP plus 3-isobutyl-1-methylxanthine for 14 h the activity of E III was increased approximately 100%. Similar activities of calcium-dependent, heat stable phosphodiesterase activator were recovered from supernatants from all cells. These studies have established the presence, in a homogeneous population of hepatoma cells, of at least three forms of cyclic nucleotide phosphodiesterase, the activities of which can be independently regulated.

Separate genetic regulation of cyclic nucleotide phosphodiesterase and its protein activator in cultured mouse fibroblasts

Dibutyryl cyclic AMP stimulated the synthesis of cyclic nucleotide phosphodiesterase (EC 3.1.4.17) but not its protein activator in normal mouse fibroblasts (3T3) and those virally transformed (3T3-SV 40). Stimulation appeared to be at the transcriptional level. These findings indicate that the increase of phosphodiesterase is not accompanied by its activator and that the two proteins are controlled by separate genes.

Characterization of Cyclic Nucleotide Phosphodiesterases of Rat Tissues

Abstract Cyclic nucleotide phosphodiesterase has been prepared from the liver, skeletal muscle, heart muscle, kidney, epididymal fat pad, and brain cortex of the rat. Kinetic analysis indicated that all of these tissues, with the exception of liver exhibit complex behavior indicative of multiple enzymatic activities. The phosphodiesterase activities of brain cortex, kidney, and adipose tissue have been resolved on Bio-Gel A-1.5m gel filtration columns into three fractions. These are an excluded fraction, a high molecular weight fraction in which the enzymatic affinity for cyclic guanosine 3',5'-monophosphate is greater than that for cyclic adenosine 3',5'-monophosphate, and a lower molecular weight fraction with a high affinity for cyclic adenosine 3',5'-monophosphate. The lower molecular weight enzyme appears to be negatively cooperative. The muscle preparations have little, if any, of the excluded fraction which in kidney, adipose tissue, and brain has kinetic behavior similar to that of the lower molecular weight enzyme. Liver has no detectable phosphodiesterase activity in any except the intermediate fraction which has a molecular weight of approximately 400,000. This enzymatic activity has been purified 88-fold by centrifugation, ammonium sulfate fractionation, and gel filtration. The potential for metabolic control through regulation of cyclic nucleotide phosphodiesterase is discussed in view of the existence of at least two distinct enzymatic activities in all of tissues studied except the liver.